An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia

• Published in: Cancers 2022-02, Vol.14 (5), p.1113
• Main Authors: Anshabo, Abel Tesfaye, Bantie, Laychiluh, Diab, Sarah, Lenjisa, Jimma, Kebede, Alemwork, Long, Yi, Heinemann, Gary, Karanjia, Jasmine, Noll, Benjamin, Basnet, Sunita K C, Li, Manjun, Milne, Robert, Albrecht, Hugo, Wang, Shudong
• Format: Article
• Language: English
• Subjects: Acute myeloid leukemia; Apoptosis; Cancer; Cell cycle; Cell proliferation; Cell survival; Clinical trials; Cyclin-dependent kinases; Drug resistance; Flt3 protein; Kinases; Leukemia; Mcl-1 protein; Mutation; Oral administration; Phosphorylation; Protein-tyrosine kinase; Proteins; Regression analysis; RNA polymerase; Transcription; Tumor cell lines; Tumorigenesis; Xenografts
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14051113

Mutations in FMS-like tyrosine kinase 3 (FLT3) occur in approximately one-third of AML patients and are associated with a particularly poor prognosis. The most common mutation, FLT3-ITD, is a self-activating internal tandem duplication (ITD) in the FLT3 juxtamembrane domain. Many FLT3 inhibitors have shown encouraging results in clinical trials, but the rapid emergence of resistance has severely limited sustainable efficacy. Co-targeting of CDK9 and FLT3 is a promising two-pronged strategy to overcome resistance as the former plays a role in the transcription of cancer cell-survival genes. Most prominently, MCL-1 is known to be associated with AML tumorigenesis and drug resistance and can be down-regulated by CDK9 inhibition. We have developed CDDD11-8 as a potent CDK9 inhibitor co-targeting FLT3-ITD with values of 8 and 13 nM, respectively. The kinome selectivity has been confirmed when the compound was tested in a panel of 369 human kinases. CDDD11-8 displayed antiproliferative activity against leukemia cell lines, and particularly potent effects were observed against MV4-11 and MOLM-13 cells, which are known to harbor the FLT3-ITD mutation and mixed lineage leukemia (MLL) fusion proteins. The mode of action was consistent with inhibition of CDK9 and FLT3-ITD. Most importantly, CDDD11-8 caused a robust tumor growth inhibition by oral administration in animal xenografts. At 125 mg/kg, CDDD11-8 induced tumor regression, and this was translated to an improved survival of animals. The study demonstrates the potential of CDDD11-8 towards the future development of a novel AML treatment.